Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Oncology Other
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Oncology Other
    New Drug Regimen Shows Promising Results for Advanced Biliary-Tract Cancers - (DGNews)
    Cancer Incidence and Mortality After Treatment With Folic Acid and Vitamin B12 - (JAMA)
    Treatment With Folic Acid, Vitamin B12 Associated With Increased Risk of Cancer, Death - (DGNews)
    Glans Resurfacing With Split-Thickness Skin Graft Helps Manage Benign and Malignant Conditions: Presented at ESSM - (DGDispatch)
    HDL Cholesterol Inversely Associated With Cancer Risk: Presented at AHA - (DGDispatch)

    News archive

     Recent webcasts/CME - Oncology Other
      Non-AIDS-Defining Cancers in Patients with HIV Infection
      Carcinoid Tumors of the Gastrointestinal Tract
      Cancer, Liver, Infections, Cardiovascular Disease, and other Biologic Agents
      Multidisciplinary Approach to Management of Neuroendocrine Tumors
      Cancer and Venous Thromboembolism: Current Clinical Issues

      Webcasts/CME archive

       Recent cases - Oncology Other
        Jejuno-Jejunal Invagination Caused by Epithelioid Sarcoma: A Case Report
        Thoracic Spinal Cord Compression Caused by Metastatic Pheochromocytoma
        Osseous Hemangioma of the Seventh Cervical Vertebra with Osteoid Formation Mimicking Metastasis: A Case Report
        Hypercalcemia in a Patient with Cholangiocarcinoma: A Case Report
        Difficult Diagnosis of Brainstem Glioblastoma Multiforme in a Woman: A Case Report and Review of the Literature

        Cases archive
          




        my personal edition > oncology other > news
        divider

          E-Mail this DGDispatch to a colleague

        DGDispatch


        Chemotherapy Sequence With Radiation Make Little Difference In Brain Tumors: Presented at ASCO

        By Ed Susman

        NEW ORLEANS, LA -- June 8, 2004 -- The sequence in which patients with brain cancer receive chemotherapy -- whether at the time of radiation therapy or when the tumor progresses -- does not appear to make a significant difference in outcomes, say Canadian researchers.

        However, there does appear to be a major difference in outcome if the brain cancer contains certain mutations, said Gregory Cairncross, MD, professor of clinical neurosciences and of oncology at the University of Alberta, Edmonton, Alberta, Canada.

        Presenting his group's findings here, June 7th, at the American Society of Clinical Oncology 40th Annual Meeting, Dr. Cairncross explained how he and his colleagues in the Radiation Therapy Oncology Group compared survival between 148 patients with anaplastic oligodendrogliomas (AO) and anaplastic oligoastrocytomas who had radiation therapy plus the chemotherapy regimen PCV which consists of procarbazine, lomustine, and vincristine, and 143 patients who had radiation therapy alone.

        Although the median survival did not differ significantly between the 2 groups -- 4.8 years for the PCV group and 4.5 years for those who had radiation alone, the time it took for the disease to progress tended to be longer in the PCV group -- 2.6 years versus 1.9 years. Severe side effects were more common in the PCV group, however.

        Since most of the patients in the radiation-only group were treated with chemotherapy once their tumors progressed, the overall survival was similar, Dr. Cairncross said, "The trial indicates that the way clinicians sequence chemotherapy with radiation does not appear to be critical in overall outcome."

        However, what did make a difference was that patients with specific chromosomal mutations -- specifically mutations of the short arm of Chromosome 1 and on the long arm of Chromosome 19 -- who had these brain cancers had a much more favorable outcome that did patients without the mutations, Dr. Cairncross said.

        About half the patients with the chromosome aberrations survived for 7 years, Dr. Cairncross said, whereas just about 10% of the patients without the mutations survived 7 years. "The difference in survival appears to be independent of the type of treatment they received in the trial," he said.

        Oligodendrogliomas with this genetic signature have a better natural history and response to treatment, said Dr. Cairncross. He suggested that oncologists may be able to use this information about the genetic differences in patients to choose the most appropriate treatment for these patients.

        [Presentation title: 1500 An intergroup randomized controlled clinical trial (RCT) of chemotherapy plus radiation (RT) versus RT alone for pure and mixed anaplastic oligodendrogliomas: Initial report of RTOG 94-02.]



        E-Mail this DGDispatch to a colleague   To print, use this version






        All contents Copyright (c) 1995-2009 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send